Why does receptor tolerance matter specifically when using a trenbolone-based cutting blend?

Trenbolone's androgen receptor affinity is approximately five times that of testosterone, which accelerates AR downregulation faster than most AAS. Once receptors begin to desensitise, the anabolic and lipolytic effects plateau regardless of dose. Mixobolin-200 addresses this by pairing trenbolone with Drostanolone Propionate — a DHT derivative that occupies AR sites competitively without equivalent downregulation pressure — and Testosterone Propionate to anchor baseline receptor sensitivity.

How does Drostanolone Propionate in Mixobolin-200 help prevent receptor downregulation compared to running trenbolone alone?

Drostanolone Propionate acts as a DHT-derived partial competitor at the androgen receptor. Unlike trenbolone's high-affinity 19-nor binding, masteron's DHT-class binding occupies receptor capacity without triggering equivalent downregulation signalling. This competitive moderation means total receptor load is distributed across two mechanistically distinct compounds rather than concentrated entirely through trenbolone's high-affinity pathway — a meaningful pharmacological distinction confirmed by the differential AR-binding kinetics of 19-nor versus DHT-class androgens.

Can short esters like those in Mixobolin-200 be used to limit cycle length as a receptor tolerance strategy?

Yes — short esters are a practical tool for tolerance cycle management. All three compounds in Mixobolin-200 carry 2–3 day half-lives, meaning plasma concentrations drop steeply within days of the final injection. This allows a practitioner to terminate the cycle promptly when performance plateaus suggest diminishing receptor responsiveness, rather than continuing under inertia as longer-ester blends require. Early cycle termination is easier to execute cleanly with propionate and acetate esters than with decanoate or enanthate-based protocols.

How should Mixobolin-200's 10x1ml single-dose ampoules be stored to maintain compound stability?

Store Mixobolin-200 ampoules at 15–25 °C, away from direct light and temperature fluctuations. Single-dose glass ampoules are sealed individually at manufacture, eliminating the multi-use contamination risk associated with vials — but once an ampoule is scored and snapped open, the entire 1ml dose must be drawn and used immediately. Do not refrigerate unless ambient temperatures consistently exceed 25 °C. Each ampoule in the 10-unit carton maintains its pharmaceutical integrity independently until point of use.

What makes single-dose glass ampoules preferable for a tri-ester blend like Mixobolin-200 compared to a multi-dose vial?

Single-dose ampoules eliminate the rubber-stopper multi-puncture contamination risk inherent to vials, which matters across a 10-injection protocol. Each ampoule is hermetically sealed at the point of manufacture under GMP aseptic conditions, ensuring the contents are exposed to atmosphere only immediately before injection. For a complex three-compound oil-based formulation like Mixobolin-200, this format preserves individual-dose sterility across the full 10-ampoule carton without requiring preservative additions or post-opening antimicrobial measures. (2) angle_used

Hardcore Cutting

BM Pharmaceuticals

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Name: Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals
Brand: BM Pharmaceuticals
SKU: INJ-MIX-BM-200-001
Price: 76.00 EUR
Availability: InStock

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Tri-ester receptor modulation: Trenbolone Acetate drives anabolic output while Drostanolone Propionate distributes AR occupancy to reduce desensitisation pressure.
Testosterone Propionate base sustains endogenous receptor responsiveness throughout the cutting protocol.
Uniform 2–3 day half-life profile across all three esters enables consistent peak plasma management and predictable washout.
10 individually hermetically sealed 1ml ampoules ensure per-dose sterility without preservative compromise.
No aromatisation from Tren A or Mast P components; oestrogen load is limited to the Testosterone Propionate fraction, simplifying aromatase inhibitor management.
Drostanolone Propionate's intrinsic anti-oestrogenic properties provide an additional hardening effect during caloric deficit phases.
Short-ester architecture supports prompt PCT initiation — clinically relevant given trenbolone's progestogenic suppression profile.

Phase	dosage	Note
Receptor Loading / Week 1–2	0.5ml every other day (100mg/ml equivalent)	Introductory phase; assess receptor response and androgenic sensitivity before progressing. Short esters reach stable plasma within 4–6 days.
Active Cutting / Week 3–6	1ml every other day (full 200mg/ml dose)	Primary tolerance management window. Monitor training performance logs — subjective plateau signals AR downregulation onset and cues cycle termination decision.
Tolerance Signal Response / Week 6–8 (conditional)	Reduce to 0.5ml every other day or terminate cycle	If performance output plateaus despite consistent training and nutrition, downregulate dose or end cycle immediately. Short esters allow a clean 3–5 day washout before PCT.
PCT Phase (post-last injection + 3–5 days)	SERM protocol (e.g., Clomiphene + Tamoxifen combination)	Aggressive dual-SERM PCT mandatory due to progestogenic suppression from Trenbolone Acetate. Standard single-SERM mini-PCT is insufficient for 19-nor compounds.

Key takeaways

Leverage Mixobolin-200's DHT-component to moderate trenbolone-driven AR downregulation.
Exploit 2–3 day half-lives to terminate cycles precisely when receptor sensitivity plateaus.
Initiate PCT 3–5 days post-injection; aggressive SERM mandatory for 19-nor suppression.
Confirm 2,000mg total active ingredient via HPLC-verified, individually sealed ampoules.
Reserve this tri-ester blend for experienced users with a defined tolerance management plan.

What Mixobolin-200 Is and Why Receptor Tolerance Defines Its Design

Mixobolin-200 is a tri-ester injectable blend formulated by BM Pharmaceuticals to address one of advanced cutting cycles' most overlooked pharmacological challenges: androgen receptor (AR) downregulation caused by high-affinity ligands. The blend contains Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per ml, totalling 200mg/ml across 10x1ml individually sealed glass ampoules. Trenbolone Acetate binds the AR with approximately five times the affinity of testosterone, making it the most potent anabolic driver in the stack — but this same high affinity accelerates receptor downregulation when used in isolation. Compared to single-compound trenbolone protocols, the tri-ester architecture of Mixobolin-200 actively counteracts this mechanism rather than ignoring it.

How Each Compound Contributes to Tolerance Management

Drostanolone Propionate — the Masteron component — functions as a DHT-derived partial competitor at the AR. It occupies receptor binding sites without triggering the same degree of downregulation associated with 19-nor compounds, effectively moderating total receptor load during the cycle. Testosterone Propionate serves as the hormonal base, preserving endogenous AR sensitivity signalling and preventing the receptor hyposensitivity that compounds like trenbolone can induce when unaccompanied. Together, these three mechanisms operate simultaneously: Trenbolone Acetate drives anabolic output, Drostanolone Propionate manages competitive receptor occupancy, and Testosterone Propionate anchors baseline androgen signalling. This stack satisfies the semantic triple of receptor management: the blend moderates AR downregulation; Masteron competes at binding sites without inducing equivalent desensitisation; Testosterone maintains receptor responsiveness throughout the protocol.

Short Esters, Cycle Control, and PCT Timing

All three esters in Mixobolin-200 carry 2–3 day half-lives, which is clinically significant for tolerance management: shorter active windows allow cycle length to be curtailed precisely when receptor sensitivity data — subjective performance plateau or training log stagnation — indicates diminishing returns. PCT initiation is recommended approximately 3–5 days after the last injection. Because trenbolone carries progestogenic activity as a 19-nor compound, an aggressive SERM protocol is mandatory rather than optional; standard testosterone-only mini-PCT strategies are insufficient here. BM Pharmaceuticals applies HPLC quantification to each ester fraction independently and LAL (Limulus Amebocyte Lysate) endotoxin testing to every batch, with each of the 10 ampoules individually sealed under GMP-compliant aseptic fill conditions to guarantee 2,000mg total active ingredient per carton.

Who Should Use This Blend

Mixobolin-200 is reserved for experienced users who already hold a tolerance management strategy and understand progestogenic suppression. It is not a first-cycle product. The 10x1ml single-dose format supports precise dosing flexibility and eliminates multi-draw contamination risk across the injection schedule.

Usage

Verify ampoule integrity before use — inspect the individually sealed glass body for cracks, particulate matter, or discolouration; do not use if the solution appears cloudy or contains visible particles.
Score the ampoule neck at the coloured break ring and snap cleanly away from the body; draw the full 1ml dose immediately using a filter needle (5-micron) to remove any glass microparticles.
Switch to an appropriately gauged injection needle (21–23G, 1–1.5 inch) for intramuscular administration; preferred sites for EOD protocols include the glute, vastus lateralis, or deltoid — rotate systematically to minimise injection site irritation from the propionate esters.
Administer every other day (EOD) to maintain stable plasma levels consistent with the 2–3 day half-lives of all three ester fractions; consistent timing reduces peak-trough variance associated with receptor sensitivity fluctuations.
Track training output objectively (strength metrics, body composition) across each week of the cycle — performance plateau signals that receptor downregulation may be outpacing the tolerance management strategy, cueing a dose reduction or cycle termination decision.
Initiate PCT 3–5 days after the final injection; prepare a dual-SERM protocol in advance given the progestogenic suppression profile of Trenbolone Acetate — do not rely on a minimal or single-agent PCT when 19-nor compounds are involved.

Warnings

contraindications: Contraindicated in individuals with known hypersensitivity to any of the three active compounds or to oil-based injectable vehicles.

Not suitable for use in individuals with active prostate pathology, hepatic impairment, or cardiovascular risk factors including unmanaged dyslipidaemia.

Strictly contraindicated in women — virilising effects from Trenbolone Acetate and Drostanolone Propionate are irreversible.

Not for first-cycle or inexperienced users; receptor tolerance management requires working knowledge of androgenic pharmacology.

side_effects: Androgenic: acne, accelerated scalp hair loss in genetically predisposed individuals, prostate stimulation.

Cardiovascular: suppression of HDL cholesterol and elevation of LDL; Trenbolone Acetate is particularly associated with adverse lipid shifts — baseline and on-cycle lipid panels are required.

Neurological/Behavioural: trenbolone-associated aggression, insomnia, and night sweats are dose-dependent and more pronounced than with testosterone-only protocols.

Progestogenic suppression: Trenbolone Acetate's 19-nor structure produces significant HPA and HPGA axis suppression via progestogenic pathways — recovery without aggressive PCT is protracted.

monitoring: Perform baseline bloodwork prior to cycle start: full lipid panel, LFT, haematocrit, PSA (males 35+), and endogenous testosterone.

Mid-cycle monitoring (week 4–5) is advisable for lipid status and haematocrit given trenbolone's haematological effects.

Blood pressure should be self-monitored weekly — trenbolone-containing protocols are associated with elevated haematocrit and subsequent BP increases.

HPLC-verified batch documentation from BM Pharmaceuticals should be cross-referenced with purchase records to confirm product authenticity.

pct: Begin PCT 3–5 days after the final Mixobolin-200 injection — the 2–3 day half-lives of all three esters allow this earlier start compared to long-ester protocols.

A dual-SERM protocol combining Clomiphene Citrate and Tamoxifen Citrate is strongly recommended given the progestogenic suppression profile of Trenbolone Acetate; a single-agent SERM carries elevated risk of incomplete HPGA axis recovery.

Standard PCT duration: 4–6 weeks minimum; extend if LH/FSH and testosterone bloodwork at week 4 indicates insufficient recovery.

Do not attempt a mini-PCT or abbreviated SERM protocol after any cycle containing a 19-nor compound — progestogenic suppression requires a more sustained recovery intervention than ester half-life alone predicts.

Frequently asked questions

Why does receptor tolerance matter specifically when using a trenbolone-based cutting blend?: Trenbolone's androgen receptor affinity is approximately five times that of testosterone, which accelerates AR downregulation faster than most AAS. Once receptors begin to desensitise, the anabolic and lipolytic effects plateau regardless of dose. Mixobolin-200 addresses this by pairing trenbolone with Drostanolone Propionate — a DHT derivative that occupies AR sites competitively without equivalent downregulation pressure — and Testosterone Propionate to anchor baseline receptor sensitivity.
How does Drostanolone Propionate in Mixobolin-200 help prevent receptor downregulation compared to running trenbolone alone?: Drostanolone Propionate acts as a DHT-derived partial competitor at the androgen receptor. Unlike trenbolone's high-affinity 19-nor binding, masteron's DHT-class binding occupies receptor capacity without triggering equivalent downregulation signalling. This competitive moderation means total receptor load is distributed across two mechanistically distinct compounds rather than concentrated entirely through trenbolone's high-affinity pathway — a meaningful pharmacological distinction confirmed by the differential AR-binding kinetics of 19-nor versus DHT-class androgens.
Can short esters like those in Mixobolin-200 be used to limit cycle length as a receptor tolerance strategy?: Yes — short esters are a practical tool for tolerance cycle management. All three compounds in Mixobolin-200 carry 2–3 day half-lives, meaning plasma concentrations drop steeply within days of the final injection. This allows a practitioner to terminate the cycle promptly when performance plateaus suggest diminishing receptor responsiveness, rather than continuing under inertia as longer-ester blends require. Early cycle termination is easier to execute cleanly with propionate and acetate esters than with decanoate or enanthate-based protocols.
How should Mixobolin-200's 10x1ml single-dose ampoules be stored to maintain compound stability?: Store Mixobolin-200 ampoules at 15–25 °C, away from direct light and temperature fluctuations. Single-dose glass ampoules are sealed individually at manufacture, eliminating the multi-use contamination risk associated with vials — but once an ampoule is scored and snapped open, the entire 1ml dose must be drawn and used immediately. Do not refrigerate unless ambient temperatures consistently exceed 25 °C. Each ampoule in the 10-unit carton maintains its pharmaceutical integrity independently until point of use.
What makes single-dose glass ampoules preferable for a tri-ester blend like Mixobolin-200 compared to a multi-dose vial?: Single-dose ampoules eliminate the rubber-stopper multi-puncture contamination risk inherent to vials, which matters across a 10-injection protocol. Each ampoule is hermetically sealed at the point of manufacture under GMP aseptic conditions, ensuring the contents are exposed to atmosphere only immediately before injection. For a complex three-compound oil-based formulation like Mixobolin-200, this format preserves individual-dose sterility across the full 10-ampoule carton without requiring preservative additions or post-opening antimicrobial measures. (2) angle_used

Manufacturer

The packaging format chosen for Mixobolin-200 reflects a deliberate decision by BM Pharmaceuticals about how a tri-ester oil-based blend of this complexity is most appropriately delivered to the end user. Single-dose 1ml glass ampoules — rather than multi-dose vials — are specified for the 10-unit Mixobolin-200 carton for reasons that go beyond convention. A three-compound blend at 200mg/ml requires that each ester fraction remain in stable suspension in the oil vehicle from fill to administration; multi-dose vials introduce repeated atmospheric exposure and rubber stopper particulate risk across successive draws that individually sealed ampoules structurally eliminate. BM Pharmaceuticals' filling line for oil-based injectables operates under nitrogen-blanketed aseptic conditions: each ampoule is filled, sealed by heat fusion, and visually inspected individually before carton assembly. The ampoule neck incorporates a colour-coded break ring calibrated for clean one-hand opening without glass fragmentation risk — a practical consideration for the EOD injection schedule that Mixobolin-200's short esters necessitate. Carton-level security includes a batch-specific holographic seal, with the serialised lot number cross-referenceable against BM Pharmaceuticals' QC release records. The 10-ampoule unit configuration is deliberate: it aligns with a standard 3–5 week EOD dosing cycle at 1ml per injection, reducing the need to open and store partially used product between sessions.

Product details

Brand	BM Pharmaceuticals
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, Gain Mix, Mixobolin-200, BM Pharmaceuticals Steroid-Mix
Strength	200 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-MIX-BM-200-001

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Best Value

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00

Cutting Specialist

Cutaxyl 150 150mg/ml 10ml Vial by Kalpa Pharmaceuticals

Cutaxyl 150 is a GMP-certified tri-ester cutting injectable by Kalpa Pharmaceuticals, combining Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml in a single 10ml multi-dose vial at 150mg/ml total concentration — formulated for compliance-conscious experienced users who demand jurisdiction-verified PCT readiness before the first injection is drawn. All three compounds carry short acetate and propionate ester chains, enabling post-cycle therapy to be scheduled as early as 3–5 days after the final dose, though SERM legal and prescription status varies materially across national regulatory frameworks and must be confirmed in advance. Each production batch exits Kalpa Pharmaceuticals' GMP facility with HPLC-verified active-ingredient concentration, LAL endotoxin clearance, and batch-traceable documentation linked to a specific, dateable manufacturing event.

€52.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00